Skip to main content

Table 3 Summary of findings

From: Topical application of mupirocin to exit sites in patients on peritoneal dialysis: a systematic review and meta-analysis of randomized controlled trials

OutcomesIllustrative comparative risk (event/100 patient-years) (95% CI)Rate ratio (95% CI)No. of participants (studies)Quality of the evidence (GRADE)
Control or gentamicinMupirocin
Comparison between the mupirocin ointment group and control group
Exit-site infection27.710.0 (3.6–29.1)0.36 (0.13–1.05)322 (3 studies)
Very low*1
Peritonitis29.723.2 (14.9–35.9)0.78 (0.50–1.21)322 (3 studies)*2
Low
Technical failure2.02.7 (0.5–14.4)1.35 (0.25–7.21)322 (3 studies)*3
Low
Comparison between the mupirocin ointment group and the gentamicin ointment group
Exit-site infection28.932.9 (7.8–138.8)1.14 (0.27–4.81)214 (2 studies)*4
Very low
Peritonitis32.327.4 (10.3–72.9)0.85 (0.32–2.26)335 (3 studies)*5
Low
Technical failure16.59.6 (4.6–19.8)0.58 (0.28–1.20)214 (3 studies)*6
Low
  1. *1Serious unexplained heterogeneity, based on studies with high risk of bias
  2. *2Based on studies with high risk of bias
  3. *3Increased risk of bias related to incomplete outcome data and selective reporting, based on studies with high risk of bias
  4. *4Increased risk of bias related to incomplete outcome data and selective reporting, based on studies with high risk of bias, serious unexplained heterogeneity
  5. *5Increased risk of bias related to incomplete outcome data and selective reporting, based on studies with high risk of bias, serious unexplained heterogeneity
  6. *6Increased risk of bias related to incomplete outcome data and selective reporting, based on studies with high risk of bias